Safety and Health at Work Vol. 11 Issue 4 2020Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders (Original Article)
Dublin Core
Title
Safety and Health at Work Vol. 11 Issue 4 2020Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders (Original Article)
Subject
Asbestos-related disorders, Biomarker, Follow-up, SMRP
Description
Background: Asbestos exposure is associated with the development of the cancer malignant mesothe-
lioma (MM). Measurement of soluble mesothelin-related protein (SMRP) has been suggested as a
method for detection of MM in its early stages. We prospectively examined SMRP levels in participants
with asbestos exposure who are a group at a high risk of development of MM.
Methods: This study was a follow-up of our cohort of 322 asbestos-exposed participants. No further
participants developed MM or malignancy over the study period. Mean follow-up time was 22.9 months.
Results: Mean (standard deviation) SMRP levels at baseline and follow-up were 0.94 (0.79) and 0.91
(0.86) nmol/L (p 1⁄4 0.1033), respectively. Mean SMRP levels of the healthy individuals exposed to asbestos at baseline was significantly lower than those of participants with asbestosis and pleural plaques alone; similar patterns were found on follow-up measurements. There was a statistically significant effect of age on serial SMRP measurements. Our study confirms higher levels in participants with nonmalignant asbestos-related disorders. Levels decreased in asbestos-related disorders other than asbestosis, where a small increase was observed. We did not detect any further cases of malignancy.
Conclusion: Monitoring programs for early detection of MM need to take into account increased SMRP levels found in benign asbestos-related diseases.
lioma (MM). Measurement of soluble mesothelin-related protein (SMRP) has been suggested as a
method for detection of MM in its early stages. We prospectively examined SMRP levels in participants
with asbestos exposure who are a group at a high risk of development of MM.
Methods: This study was a follow-up of our cohort of 322 asbestos-exposed participants. No further
participants developed MM or malignancy over the study period. Mean follow-up time was 22.9 months.
Results: Mean (standard deviation) SMRP levels at baseline and follow-up were 0.94 (0.79) and 0.91
(0.86) nmol/L (p 1⁄4 0.1033), respectively. Mean SMRP levels of the healthy individuals exposed to asbestos at baseline was significantly lower than those of participants with asbestosis and pleural plaques alone; similar patterns were found on follow-up measurements. There was a statistically significant effect of age on serial SMRP measurements. Our study confirms higher levels in participants with nonmalignant asbestos-related disorders. Levels decreased in asbestos-related disorders other than asbestosis, where a small increase was observed. We did not detect any further cases of malignancy.
Conclusion: Monitoring programs for early detection of MM need to take into account increased SMRP levels found in benign asbestos-related diseases.
Creator
Eun-Kee Park, Anthony R. Johnson, Donald Wilson, Paul S. Thomas, Deborah H. Yates
Publisher
Elsevier Korea LLC
Date
December 2020
Contributor
Sri Wahyuni
Format
PDF
Language
English
Type
Text
Coverage
Safety and Health at Work Vol. 11 Issue 4 2020
Files
Citation
Eun-Kee Park, Anthony R. Johnson, Donald Wilson, Paul S. Thomas, Deborah H. Yates , “Safety and Health at Work Vol. 11 Issue 4 2020Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders (Original Article),” Repository Horizon University Indonesia, accessed November 21, 2024, https://repository.horizon.ac.id/items/show/2042.